ArticleEcoSal Plus2019
Curli Biogenesis: Bacterial Amyloid Assembly by the Type VIII Secretion Pathway.
Article in EcoSal Plus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 65 citations in OpenAlex.
- Cross-species genomic analysis ofOne health (Amsterdam, Netherlands) · 2026Article
- Fermented Navy Bean-Derived Agents Restore Antibiotic Susceptibility inJournal of microbiology and biotechnology · 2026Article
- From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026Review
- Review
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- The cytoplasmic protein YedX is a potent inhibitor of CsgA amyloid assembly in E. coli.The Journal of biological chemistry · 2026Article
- PLM-effector: unleashing the potential of protein language models for bacterial secreted protein prediction.Briefings in bioinformatics · 2026Article
- βProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Salmonellosis as a One Health-One Biofilm Challenge: Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2025Review
- Repurposing the bacterial surface display technology for drug delivery.Advanced drug delivery reviews · 2025Review
- Genomic Drivers of Biofilm Formation inMicroorganisms · 2025Article
- Surface protein machineries in Gram-negative bacteria.Journal of cell science · 2025Review
- Article
- Bacterial Species in Engineered Living Materials: Strategies and Future Directions.Microbial biotechnology · 2025Review
- Characterizing host-microbe interactions with bacterial effector proteins using proximity-dependent biotin identification (BioID).Communications biology · 2025Review
- Pathogenesis and Immunomodulation of Urinary Tract Infections Caused by UropathogenicMicroorganisms · 2025Review
- Capturing the micro-communities: Insights into biogenesis and architecture of bacterial biofilms.BBA advances · 2025Article
- A molecular toolkit for heterologous protein secretion across Bacteroides species.Nature communications · 2024Article
- Type 1 secretion necessitates a tight interplay between all domains of the ABC transporter.Scientific reports · 2024Article
- A molecular toolkit for heterologous protein secretion acrossbioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
In 1989, Normark and coworkers reported on fibrous surface structures called curli on strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.